

STATE OF NEVADA DEPARTMENT OF HUMAN RESOURCES

MICHAEL J. WILLDEN Director

CHARLES DUARTE
Administrator

DIVISION OF HEALTH CARE FINANCING AND POLICY

NEVADA MEDICAID

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy ("DHCFP") Pharmaceutical and Therapy Committee will conduct a public meeting on October 27, 2005 beginning at 12:00 p.m. at the following location:

Las Vegas Library Multipurpose Room 833 Las Vegas Blvd., North Las Vegas, NV 89101

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Nancy Davis at: 775-684-3715 or toll free at: 1-800-992-0900, ext. 43715 in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

This meeting is a continuance of the meeting initially held on July 28, 2005. Agenda items II through VI are continued from the meeting initially held on July 28, 2005, but not completed. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment may be limited to 3 minutes per person or per company/product at the discretion of the Chairperson.

AGENDA

- I. Call to Order and Roll Call
- II. Drug Classes without Proposed Changes
 - A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy without Changes
 - 1. Antibiotics: Cephalosporins 2nd Generation
 - 2. Antibiotics: Cephalosporins 3rd Generation
 - 3. Antibiotics: Macrolides
 - 4. Antibiotics: Quinolones 3rd Generation
 - 5. Antiemetics: Oral, 5-HT3s
 - 6. Antifungals: Onychomycosis Agents
 - 7. Cardiovascular: Ace Inhibitors & Diuretic Combinations
 - 8. Cardiovascular: Angiotensins II Receptor Blockers & Diuretic Combination
 - 9. Cardiovascular: Beta Blockers
 - 10. Cardiovascular: Calcium Channel Blockers & ACEI Combinations
 - 11. Central Nervous System: ADHD/Stimulants/Non-Stimulants
 - 12. Erectile Dysfunction Agents
 - 13. Gastrointestinal Agents: H2RAs
 - 14. Gastrointestinal Agents: PPIs
 - 15. Glaucoma Agents: Beta-Blockers, Alpha adrenergics, Carbonic Anhydrase Inhibitors
 - 16. Hepatitis C Agents
 - 17. Herpetic Antiviral Agents
 - 18 Leukotriene Modifiers
 - 19. Respiratory: Glucocorticoids, Inhalers
 - 20. Respiratory: Glucocorticoids, Nasal

- B. * Committee Discussion and Approval of Drug Classes without changes for the PDL
- III. Glaucoma Agents-Postaglandins
 - A. Public Comment
 - B. Drug Class Review Presentation First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- IV. Respiratory: Anticholinergic Agents, Inhaled
 - A. Public Comment
 - B. Drug Class Review Presentation First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- V. Respiratory Agents: Beta-Adrenergic Agents, Long-Acting Inhaled
 - A. Public Comment
 - B. Drug Class Review Presentation First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VI. Respiratory Agents: Beta-Adrenergic Agents, Short-Acting Inhaled
 - A. Public Comment
 - B. Drug Class Review Presentation First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VII. Presentation on the Continuation of the Grandfathering Policy for Antidepressants by First Health Services
 - A. Public Comment
 - B. *Committee Discussion and Action on Continuation of Grandfathering for Antidepressant Medications
- VIII. Review of Next Meeting Locations, Dates, and Times
- IX. Public Comment
- X. *Adjournment
- * Denotes items, including subparts, on which an action may be taken.

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcfp@state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.